Each of our product candidates is created with our proprietary SMART linker drug discovery platform to address a critical challenge in drug discovery: modulating multiple biological targets simultaneously to treat diseases successfully. Catabasis's pipeline focuses the use of this technology in rare diseases.
Leveraging the growing body of knowledge about disease pathways, we’ve learned that chemically linking bioactives enables us to shepherd them directly into cells, resulting in the bioactives reaching their targets in the same cells at the same time and producing novel pharmacology.
We use our SMART linker drug discovery platform to conjugate two separate bioactives with known pharmacological activity. For examples, edasalonexent (CAT-1004) is a conjugate of salicylic acid and docosahexaenoic acid (DHA), CAT-4001 is a conjugate of monomethyl fumarate and DHA, CAT-5571 is a conjugate of cysteamine and DHA and the CAT-2000 series are conjugates of eicosapentaeonic acid (EPA) and nicotinic acid. Our technology renders the bioactive inactive in the circulation so safety of the molecule may be improved compared to the individual separate bioactives. Specific enzymes release the component bioactives inside the cell where they are able to simultaneously modulate multiple biological targets which we believe drive enhanced efficacy. In short, our newly-created molecules act like a two-pronged drug candidate with potential for enhanced efficacy and improved safety and tolerability compared to individual separate bioactives.
Visit our pipeline page to see what we are working on.